Skip to content

Clinical evaluation of Siddha drug Velli parpam for prostatomegaly(Enlarge prostate)

Phase II non-randomized open clinical evaluation of Siddha drug VELLI PARPAM for PITHA MOOTHIRA KIRICHARAM (Benign prostate hypertrophy) in Male between 40 to 80 age group attending OPD at AAGHIM attached with GSMC

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/08/020979
Enrollment
20
Registered
2019-08-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: VELLI PARPAM: 130mg once a day with ghee for 48 days Control Intervention1: Nil: Nil

Sponsors

Govt Siddha Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Isolated BPH symptoms BPH with lower urinary tract symptoms PSA (prostate specific antigen) with in the normal limit ( USG prostate volume not more than 75 cc ( stage I â?? 25 cc to 50 cc and stage II â?? 50 cc to 75 cc)

Exclusion criteria

Exclusion criteria: Age 80 yrs male Acute urinary retention CA prostate Acute and chronic renal failure Diabetic nephropathy Post TURP states Stricture urethra Urinary bladder calculus Any severe life threatening illness Nephrotic and nephritic syndrome PSA more than 4 nm/ml [5]. USG Prostate volume more than 80CC Acute pyelonephritis Obstructive uropathy Prostatitis

Design outcomes

Primary

MeasureTime frame
Reduced in clinical symptoms using IPSS assessing scale Timepoint: 48 days

Secondary

MeasureTime frame
Monitoring the reduction in the size of the gland from stage II to stage I and from stage I to normal using ultrasonographyTimepoint: 48 days

Countries

India

Contacts

Public ContactDr E VIVEKANANDHAN

Govt Siddha Medical College

nanbu.sumi@gmail.com9443279412

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026